Drug Profile
Research programme: G protein-coupled receptor antagonists - ICOS
Latest Information Update: 30 Mar 2009
Price :
$50
*
At a glance
- Originator ICOS Corporation
- Developer Eli Lilly and Company
- Class
- Mechanism of Action G protein-coupled receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 30 Mar 2009 No development reported - Preclinical for Inflammation in USA (unspecified route)
- 29 Jan 2007 ICOS Corporation has been acquired by Eli Lilly and Company
- 07 Jul 2006 This programme is still in active development